157604-46-1

Usage

Uses

Used in Dietary Supplements:
3-(1,1-DIMETHYLETHYL)-4-METHYL-(R,S)-2,2-DIMETHYL-3,4-OXAZOLIDINEDICARBOXYLATE is used as a dietary supplement for supporting energy production and muscle function. It aids in the conversion of fatty acids into energy, thereby enhancing physical endurance and athletic performance.
Used in Healthcare:
In the healthcare industry, 3-(1,1-DIMETHYLETHYL)-4-METHYL-(R,S)-2,2-DIMETHYL-3,4-OXAZOLIDINEDICARBOXYLATE is used for its potential benefits in managing conditions such as heart disease, diabetes, and certain neurological disorders. Its role in energy metabolism makes it a subject of interest for therapeutic applications.

InChI:InChI=1/C12H21NO5/c1-10(2,3)18-9(16)13-11(4,5)17-7-12(13,6)8(14)15/h7H2,1-6H3,(H,14,15)/t12-/m1/s1

Upstream product

• 69942-12-7 N-tert-butoxycarbonylserine methyl ester 
• 77-76-9 2,2-dimethoxy-propane 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 108149-63-9 4-hydroxymethyl-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 108149-63-9 tert-butyl (4S)-4-(hydroxymethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 95715-87-0 tert-butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate 
• 95715-86-9 (S)-2,2-dimethyl-oxazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 4-methyl ester 
• 108149-60-6 methyl [(4R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidin-4-yl]carboxylate 

Relevant academic research and scientific papers

BIARYL KINASE INHIBITORS

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

SPHINGOSINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND SPHINGOMYELINASE INHIBITOR

An object of the invention is to provide a novel sphingosine compound with an inhibitory activity against sphingomyelinase, and a method for producing the sphingosine compound. The novel sphingosine compound or a salt thereof according to the invention is represented by Formula (1): wherein one of R1 and R2 is hydrogen, and the other is a group represented by Formula (G): wherein n is 0 or 1; and R3 is hydrogen, C1-23 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C1-6 alkoxy, C3-8 cycloalkyloxy, phenyl, or furil.

A solid-phase approach to DDB derivatives

Since the discovery of 2,2′-dimethoxycarbonyl-4,4-dimethoxy-5,6, 5′,6′-biomethylenedioxy-biphenyl (DDB) as a potent anti-HBV agent, we have studied the structure-activity relationships of 4,4′-dimethoxy-5, 6,5′,6′-dimethenedioxy-2-alkyloxycarbonyl-2′-(4-substituted benzyl piperazin-1-yl)carbonyl-biphenyl as anti-HBV agents. Therefore, it is rational to extend this study to the 3,3′-disustituted-4,4′- dimethoxy-5,6,5′,6′-dimethenedioxy-2-alkyloxycarbonyl-2′- Serine derivatives. Thus, in an attempt to develop an efficient method for the preparation of a large number of DDB derivatives, the reaction between a DDB acid chloride and serine derivatives on solid support was studied. The structure of resulted compounds was confirmed by LC-MS and 1H NMR analysis. Compounds 2a, 2d, 2f, 2j showed in vitro anti-HBV activity without significant toxicity up to 100 μM.